SEC Form 4 · accession 0000891293-15-000032
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Sep 4, 2015
Accepted (ET)
Sep 4, 2015 · 6:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2015 | F | 12,526 | $1.52 | D | 659,214 | D | |
| Common Stock | Sep 4, 2015 | S | 5,500 | $1.53 | D | 653,714 | D | |
| Common Stock | Sep 4, 2015 | S | 1,700 | $1.535 | D | 652,014 | D | |
| Common Stock | Sep 4, 2015 | S | 1,000 | $1.54 | D | 651,014 | D | |
| common Stock | Sep 4, 2015 | S | 1,800 | $1.55 | D | 649,214 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld by CTIC to satisfy minimum tax withholding obligations on the vesting of restricted stock.
- F2The sale was effected pursuant to a Rule 10b5-1 trading plans.